Objective: To determine the frequency of white-coat hypertension (WCH) and associated risk factors in recently diagnosed hypertensive patients.
Material And Methods: A cross-sectional study was carried out from January 1997 to December 1998. The reference population consisted of 195 patients presenting with systemic arterial hypertension (SAH) of less than 1-month evolution and receiving no medical treatment. According to Joint National Committee (JNCVI) criteria, 100 individuals with Stages I, II, and III SAH underwent the following procedures: clinical history; physical examination; electrocardiogram, serum creatinine; urianalysis, and ambulatory monitoring of arterial pressure (AMAP).
Results: A total of 54% of patients were WCH carriers and 46% presented sustained hypertension (SH); 37% of WCH patients and 63% of SH patients had a family history of SAH, while 19.7% of WCH patients and 39.2% of SH patients presented with stage 1 retinopathy. Left ventricular hypertrophy was absent in all WCH patients and present in 21.7% of SH patients. A total of 31% of WCH patients and 50% of SH patients presented electrocardiographic changes.
Conclusions: A total of 54% of patients presented WCH. Clinical/epidemiologic profiles of WCH carriers and SH patients are different.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Association of clinical phenotypes of depression with comorbid conditions, treatment patterns and outcomes: a 10-year region-based cohort study.
Transl Psychiatry
December 2024
West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Depression is a heterogeneous and complex psychological syndrome with highly variable manifestations, which poses difficulties for treatment and prognosis. Depression patients are prone to developing various comorbidities, which stem from different pathophysiological mechanisms, remaining largely understudied. The current study focused on identifying comorbidity-specific phenotypes, and whether these clustered phenotypes are associated with different treatment patterns, clinical manifestations, physiological characteristics, and prognosis.
View Article and Find Full Text PDFFully automated MRI-based convolutional neural network for noninvasive diagnosis of cirrhosis.
Insights Imaging
December 2024
Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Objectives: To develop and externally validate a fully automated diagnostic convolutional neural network (CNN) model for cirrhosis based on liver MRI and serum biomarkers.
Methods: This multicenter retrospective study included consecutive patients receiving pathological evaluation of liver fibrosis stage and contrast-enhanced liver MRI between March 2010 and January 2024. On the training dataset, an MRI-based CNN model was constructed for cirrhosis against pathology, and then a combined model was developed integrating the CNN model and serum biomarkers.
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Lancet Oncol
December 2024
British Columbia Cancer Agency, Vancouver, BC, Canada.
Background: Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are available in the post-cyclin-dependent kinase 4/6 inhibitor setting. BYLieve aimed to assess alpelisib plus endocrine therapy in this setting in three cohorts defined by immediate previous treatment; here, we report results from cohort A.
Methods: This ongoing, phase 2, multicentre, open-label, non-comparative study enrolled patients with hormone receptor-positive, HER2-negative, advanced breast cancer with tumour PIK3CA mutation, following progression on or after previous therapy, including CDK4/6 inhibitors, from 114 study locations (cancer centres, medical centres, university hospitals, and hospitals) in 18 countries worldwide.
Integrative Analysis Identifies NSUN2 as an Essential Coordinator for Glioma Malignancy and Glucose Metabolism.
J Gene Med
December 2024
Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.
Background: Glioma, particularly glioblastoma, is the most common and aggressive primary brain tumor, with poor prognosis due to its metabolic heterogeneity. NSUN2, an m5C RNA methyltransferase and direct glucose sensor, has been implicated in various malignancies, but its role in glioma remains unclear.
Methods: Bioinformatic analysis was performed on multiple public databases and our glioma dataset from West China Hospital (WCH).
Integrated analyses of multi-omic data derived from paired primary lung cancer and brain metastasis reveal the metabolic vulnerability as a novel therapeutic target.
Genome Med
November 2024
Department of Neurosurgery/Neuro-Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
Background: Lung cancer brain metastases (LC-BrMs) are frequently associated with dismal mortality rates in patients with lung cancer; however, standard of care therapies for LC-BrMs are still limited in their efficacy. A deep understanding of molecular mechanisms and tumor microenvironment of LC-BrMs will provide us with new insights into developing novel therapeutics for treating patients with LC-BrMs.
Methods: Here, we performed integrated analyses of genomic, transcriptomic, proteomic, metabolomic, and single-cell RNA sequencing data which were derived from a total number of 154 patients with paired and unpaired primary lung cancer and LC-BrM, spanning four published and two newly generated patient cohorts on both bulk and single cell levels.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!